Loading...

CRBP CORBUS PHARMACEUTICALS HOLDINGS INC Earnings Reports 8-K Filing

CRBS

CRBP

CORBUS PHARMACEUTICALS HOLDINGS INC

(CRBP)

2025 8-K

Summary

Summary

Financial Update

Clinical Study Results

FDA Fast Track Approval

Financial Statements

Financial Statements

Management Change

Financial Results

Clinical Trial Update

Share Sale Plan

Financial Results

Stock Sale Plan

Presentation Update

Financial Results

Rule 10b5-1 Plan

Phase 1 Clinical Trial Data...

Equity Compensation Plan Ap...

Risk Factors Update

Financial Results

Amended Employment Agreements

Rule 10b5-1 Plans Adopted

Financial Results

Update on Investor Presenta...

Amendment Filing

Underwriting Agreement

Termination of Prospectus S...

Financial Update

Clinical Trial Data Announc...

Delisting Notice

Update of Presentation

Delisting Notice

Financial Results

Financial Results

Financial Results

Financial Results and Manag...

Appointment of Director

Exclusive License Agreement...

Delisting Notice

External Links:

Corbus Pharmaceuticals expects to have approximately $104 million in cash and investments as of September 30, 2025, including $27 million in cash. This is a preliminary estimate and may change before final results are reported.

AI Assistant

CORBUS PHARMACEUTICALS HOLDINGS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.